Amicus Therapeutics (FOLD) News Today $9.58 -0.06 (-0.62%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$9.59 +0.01 (+0.05%) As of 01/31/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law FirmJanuary 30 at 2:43 PM | investing.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Position Decreased by Inspire Investing LLCInspire Investing LLC lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 38.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,151 shares of the biopharmaceutical company's stock afterJanuary 26, 2025 | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement CasesJanuary 23, 2025 | globenewswire.comResearch Analysts Offer Predictions for FOLD Q2 EarningsJanuary 23, 2025 | americanbankingnews.comQ4 EPS Forecast for Amicus Therapeutics Lifted by AnalystJanuary 23, 2025 | americanbankingnews.comLeerink Partnrs Issues Optimistic Outlook for FOLD EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for Amicus Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceuticJanuary 22, 2025 | marketbeat.comIs Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 21, 2025 | msn.comQ2 Earnings Forecast for FOLD Issued By Leerink PartnrsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Amicus Therapeutics in a note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical company will post eJanuary 21, 2025 | marketbeat.comAssenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Assenagon Asset Management S.A. reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 76.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 476,782 shares of the biopharmaceutiJanuary 21, 2025 | marketbeat.comAmicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | insidermonkey.comPositive Outlook for Amicus Therapeutics: Strong Galafold Performance and Strategic Expansion Plans for Future GrowthJanuary 15, 2025 | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by AnalystsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy raJanuary 15, 2025 | marketbeat.comAmicus Therapeutics: Strong Revenue Performance and Positive Outlook Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comNCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act EnjoinedJanuary 13, 2025 | globenewswire.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Here's What HappenedAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Should You Buy?January 13, 2025 | marketbeat.comAmicus reports preliminary FY24 revenue of $528M, consensus $526.12MJanuary 13, 2025 | markets.businessinsider.comAmicus Therapeutics: Balancing Strong Revenue Growth with Execution Risks and Market Valuation ConcernsJanuary 13, 2025 | markets.businessinsider.comShareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past weekJanuary 13, 2025 | finance.yahoo.comNeedham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD)Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Monday.January 13, 2025 | marketbeat.comAmicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025January 12, 2025 | gurufocus.comAmicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic OutlookJanuary 12, 2025 | gurufocus.comAmicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025January 12, 2025 | gurufocus.comAmicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025January 12, 2025 | gurufocus.comAmicus Therapeutics Reports 32% Revenue Growth in 2024, Anticipates Continued Expansion in 2025January 12, 2025 | quiverquant.comAmicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic OutlookJanuary 12, 2025 | gurufocus.comAmicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025January 12, 2025 | gurufocus.comAmicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025January 12, 2025 | gurufocus.comAmicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic OutlookJanuary 12, 2025 | globenewswire.comIs Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20?January 12, 2025 | insidermonkey.comAmicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year Low - Here's What HappenedAmicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month Low - Time to Sell?January 10, 2025 | marketbeat.comPrincipal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Principal Financial Group Inc. lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 88.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,275 sharesJanuary 7, 2025 | marketbeat.comAmicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co.JPMorgan Chase & Co. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 13.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,919,929 shares of the biopharmaceuJanuary 2, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest UpdateAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 19,600,000 shares, a decrease of 5.9% from the November 30th total of 20,830,000 shares. Based on an average trading volume of 2,550,000 shares, the days-to-cover ratio is currently 7.7 days.January 1, 2025 | marketbeat.comAmicus Therapeutics: Cheap Heading Into 2025December 27, 2024 | seekingalpha.comAmicus Therapeutics: Cheap Heading Into 2025December 27, 2024 | seekingalpha.comNCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote ItDecember 23, 2024 | globenewswire.comGeode Capital Management LLC Has $70.50 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Geode Capital Management LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,599,871 shares of the biopharmaceutical company's stock after purchasing an additioDecember 22, 2024 | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency ActDecember 18, 2024 | globenewswire.comJefferies Issues a Buy Rating on Amicus (FOLD)December 18, 2024 | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Lowered to "Hold" Rating by StockNews.comStockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday.December 18, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Lessened by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 66.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,007 shares of the biophaDecember 17, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Up 5.2% - Here's What HappenedAmicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2% - Still a Buy?December 16, 2024 | marketbeat.comOrion Portfolio Solutions LLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Orion Portfolio Solutions LLC lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 36.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 92,648 shares of the biopharmaceutical company's stock afteDecember 16, 2024 | marketbeat.comMorgan Stanley Downgrades Amicus Therapeutics (FOLD)December 14, 2024 | msn.comRetired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her SuspensionDecember 13, 2024 | globenewswire.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's WhyAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's What HappenedDecember 13, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Given "Equal Weight" Rating at Morgan StanleyMorgan Stanley restated an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday.December 13, 2024 | marketbeat.com65,786 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Neo Ivy Capital ManagementNeo Ivy Capital Management bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 65,786 shares of the biopharmaceutical company's sDecember 12, 2024 | marketbeat.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼1.160.69▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼35▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXAS News EXEL News RGEN News HALO News MDGL News IONS News ALKS News LGND News GERN News DVAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
